tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Mycobacterium Infections, Nontuberculous D009165 8 associated lipids
Nail Diseases D009260 2 associated lipids
Paronychia D010304 3 associated lipids
Duodenal Ulcer D004381 12 associated lipids
Dyspnea D004417 10 associated lipids
Vascular Diseases D014652 16 associated lipids
Heart Defects, Congenital D006330 20 associated lipids
Listeriosis D008088 12 associated lipids
Connective Tissue Diseases D003240 2 associated lipids
Ascites D001201 25 associated lipids
Albuminuria D000419 18 associated lipids
Anemia D000740 21 associated lipids
Osteomalacia D010018 5 associated lipids
Tremor D014202 15 associated lipids
Pemphigoid, Bullous D010391 8 associated lipids
Vasculitis D014657 14 associated lipids
Hypothermia D007035 19 associated lipids
Parkinson Disease D010300 53 associated lipids
Down Syndrome D004314 18 associated lipids
Adrenal Insufficiency D000309 3 associated lipids
Keloid D007627 12 associated lipids
Nephritis D009393 19 associated lipids
Food Hypersensitivity D005512 7 associated lipids
Respiration Disorders D012120 5 associated lipids
Thymus Neoplasms D013953 15 associated lipids
Uterine Cervical Dysplasia D002578 2 associated lipids
Facial Neoplasms D005153 3 associated lipids
Dysgammaglobulinemia D004406 3 associated lipids
Influenza, Human D007251 11 associated lipids
Immune System Diseases D007154 3 associated lipids
Headache D006261 4 associated lipids
Cystitis D003556 23 associated lipids
Sarcoma, Kaposi D012514 6 associated lipids
HIV Infections D015658 20 associated lipids
Drug Eruptions D003875 30 associated lipids
Folliculitis D005499 7 associated lipids
Blindness D001766 6 associated lipids
Oliguria D009846 2 associated lipids
Dyskinesia, Drug-Induced D004409 15 associated lipids
Dermatitis, Allergic Contact D017449 20 associated lipids
Graves Disease D006111 6 associated lipids
Peptic Ulcer Perforation D010439 3 associated lipids
Gout D006073 4 associated lipids
Papillomavirus Infections D030361 4 associated lipids
Choline Deficiency D002796 16 associated lipids
Anemia, Hemolytic, Autoimmune D000744 5 associated lipids
Biliary Fistula D001658 13 associated lipids
Glomerulonephritis, Membranoproliferative D015432 3 associated lipids
Glomerulonephritis, Membranous D015433 6 associated lipids
Renal Insufficiency D051437 8 associated lipids
Ventricular Dysfunction, Left D018487 33 associated lipids
Hyperparathyroidism, Secondary D006962 4 associated lipids
Neuritis D009443 4 associated lipids
Hypertension, Portal D006975 12 associated lipids
Genetic Predisposition to Disease D020022 24 associated lipids
Hepatitis C D006526 7 associated lipids
Lichen Planus D008010 3 associated lipids
Sclerosis D012598 5 associated lipids
Atherosclerosis D050197 85 associated lipids
Leukemia-Lymphoma, Adult T-Cell D015459 25 associated lipids
Insulin Resistance D007333 99 associated lipids
Liver Failure, Acute D017114 11 associated lipids
Diabetes Complications D048909 4 associated lipids
Pulmonary Disease, Chronic Obstructive D029424 16 associated lipids
Dental Pulp Calcification D003784 2 associated lipids
Hepatitis C, Chronic D019698 12 associated lipids
Coronary Stenosis D023921 6 associated lipids
Dehydration D003681 11 associated lipids
Hemophilia A D006467 10 associated lipids
Encephalitis D004660 15 associated lipids
Dyslipidemias D050171 7 associated lipids
Fatigue D005221 10 associated lipids
Meningoencephalitis D008590 4 associated lipids
Gynecomastia D006177 6 associated lipids
Thyroiditis, Autoimmune D013967 9 associated lipids
Myxedema D009230 2 associated lipids
Pregnancy Complications D011248 19 associated lipids
Candidiasis, Oral D002180 11 associated lipids
Stomatitis D013280 14 associated lipids
Biliary Tract Neoplasms D001661 7 associated lipids
Lung Diseases, Interstitial D017563 5 associated lipids
Weight Loss D015431 56 associated lipids
Tinea D014005 5 associated lipids
Critical Illness D016638 13 associated lipids
Endotoxemia D019446 27 associated lipids
Neoplasm Invasiveness D009361 23 associated lipids
Memory Disorders D008569 33 associated lipids
Glucose Intolerance D018149 13 associated lipids
Dry Eye Syndromes D015352 10 associated lipids
Thinness D013851 11 associated lipids
Opportunistic Infections D009894 8 associated lipids
Eczema D004485 4 associated lipids
Neurodegenerative Diseases D019636 32 associated lipids
Vasculitis, Leukocytoclastic, Cutaneous D018366 5 associated lipids
Rhabdomyolysis D012206 9 associated lipids
Lupus Nephritis D008181 8 associated lipids
Telangiectasis D013684 2 associated lipids
Anemia, Iron-Deficiency D018798 6 associated lipids
Parkinsonian Disorders D020734 20 associated lipids
Ventricular Remodeling D020257 28 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Gaweco AS et al. Distinct intragraft cytokine gene expression patterns during acute hepatic rejection under cyclosporine versus FK 506 primary immunosuppression. 1994 Transplant. Proc. pmid:7527948
Fruman DA et al. Immunophilins in protein folding and immunosuppression. 1994 FASEB J. pmid:7513288
Mathieu C et al. Potential role of 1,25(OH)2 vitamin D3 as a dose-reducing agent for cyclosporine and FK 506. 1994 Transplant. Proc. pmid:7527950
Piekoszewski W et al. Pharmacokinetic and pharmacodynamic effects of coadministration of methylprednisolone and tacrolimus in rabbits. 1994 J. Pharmacol. Exp. Ther. pmid:7513355
Mueller AR et al. Severe neurotoxicity after liver transplantation: association between FK 506 therapy and hepatitis C virus disease. 1994 Transplant. Proc. pmid:7527951
Ueki M et al. Peritoneal-omental pouch as a site for islet allotransplantation. 1994 Transplant. Proc. pmid:7513462
Platz KP et al. Causes of death following liver transplantation in FK 506- and cyclosporine-treated patients. 1994 Transplant. Proc. pmid:7527952
Yasunami Y et al. Acceptance of donor-specific islet allografts in rat by intraportal preimmunization with islets and FK 506. 1994 Transplant. Proc. pmid:7513467
Christe W Neurological disorders in liver and kidney transplant recipients. 1994 Transplant. Proc. pmid:7527953
Ueki M et al. Functional and morphologic characterization of renal subcapsular islet isografts in rats treated with FK 506. 1994 Transplant. Proc. pmid:7513469
Tze WJ et al. Immunohistochemical studies of pig islet xenograft in rats immunosuppressed with FK 506. 1994 Transplant. Proc. pmid:7513470
Tze WJ et al. Prolongation of pig islet xenograft survival in rats by local immunosuppression with FK 506. 1994 Transplant. Proc. pmid:7513471
Fukuzaki T et al. Nonvascularized islet xenograft rejection in a mouse-to-rat combination where the vascularized heart is rapidly rejected. 1994 Transplant. Proc. pmid:7513472
Stan R et al. Interaction between FKBP12-rapamycin and TOR involves a conserved serine residue. 1994 J. Biol. Chem. pmid:7528205
Hachida M et al. [The rescue effect of FK506 in refractory rejection after cardiac transplantation]. 1994 Nihon Kyobu Geka Gakkai Zasshi pmid:7528255
Sugiyama E et al. FK506, an immunosuppressant, partially inhibits interleukin 6 production by adherent rheumatoid synovial cells. 1994 J. Rheumatol. pmid:7528280
Chen TS et al. Microbial transformation of immunosuppressive compounds. IV. Hydroxylation and hemiketal formation of ascomycin (immunomycin) by Streptomyces sp. MA 6970 (ATCC No. 55281). 1994 J. Antibiot. pmid:7531195
Brillantes AB et al. Stabilization of calcium release channel (ryanodine receptor) function by FK506-binding protein. 1994 Cell pmid:7514503
Bennett WM et al. Nephrotoxicity of immunosuppressive drugs. 1994 Nephrol. Dial. Transplant. pmid:7528363
Bennett WM et al. Nephrotoxicity of immunosuppressive drugs. 1994 Miner Electrolyte Metab pmid:7531274
McCashland TM et al. Bile acid metabolism and biliary secretion in patients receiving orthotopic liver transplants: differing effects of cyclosporine and FK 506. 1994 Hepatology pmid:7514561
Husi H et al. Mapping of the immunophilin-immunosuppressant site of interaction on calcineurin. 1994 J. Biol. Chem. pmid:7514602
Moudgil A et al. Inhibition of in vitro immunoglobulin production by a novel immunosuppressive drug brequinar sodium. 1994 Transplant Sci pmid:7528627
Sekigawa I et al. FK506 can inhibit apoptotic cell death induced by the HIV-1 envelope glycoprotein gp120. 1994 AIDS pmid:7531458
Mazariegos GV et al. Rubella infection after orthotopic liver transplantation. 1994 Pediatr. Infect. Dis. J. pmid:7514783
Klaus GG et al. Properties of mouse CD40. Ligation of CD40 activates B cells via a Ca(++)-dependent, FK506-sensitive pathway. 1994 Eur. J. Immunol. pmid:7528676
Mañez R et al. Fluconazole therapy in transplant recipients receiving FK506. 1994 Transplantation pmid:7515201
Tzakis AG et al. Intestinal transplantation. 1994 Annu. Rev. Med. pmid:7515221
Foster CA et al. Pharmacological modulation of endothelial cell-associated adhesion molecule expression: implications for future treatment of dermatological diseases. 1994 J. Dermatol. pmid:7531725
Nishimori H et al. Combination therapy with FK 506 and splenectomy may induce tolerance in cardiac xenografts. 1994 Transplant. Proc. pmid:7518102
Kawauchi M et al. Cardiac xenotransplantation from pig to Japanese monkey with splenectomy, tacrolims, filtration plasmapheresis, and nafamstat mesilate. 1994 Transplant. Proc. pmid:7518105
Ohtsuka S et al. Effect of splenectomy on hamster-to-rat pancreas xenotransplantation. 1994 Transplant. Proc. pmid:7518109
Yasutomi M et al. Mechanism of antibody production in hamster-to-rat concordant xenotransplantation: establishment of a simple model using intravenous injection of concordant splenocytes. 1994 Transplant. Proc. pmid:7518110
Miyazawa H et al. Mechanisms of hamster kidney graft rejection in the rat. 1994 Transplant. Proc. pmid:7518111
Nardo B et al. Pretransplant xenogeneic blood transfusion combined with FK 506 prolongs hamster-to-rat liver xenograft survival. 1994 Transplant. Proc. pmid:7518112
Pan F et al. FK 506 prolongs survival of liver but not heart mouse-to-rat vascularized xenografts. 1994 Transplant. Proc. pmid:7518113
Valdivia LA et al. Complement and target cells belong to the same species after liver xenografting: protection from hyperacute rejection. 1994 Transplant. Proc. pmid:7518123
Helekar SA et al. Prolyl isomerase requirement for the expression of functional homo-oligomeric ligand-gated ion channels. 1994 Neuron pmid:7507339
Parsons JN et al. Regulation of calcineurin phosphatase activity and interaction with the FK-506.FK-506 binding protein complex. 1994 J. Biol. Chem. pmid:7518461
Cunningham KW and Fink GR Calcineurin-dependent growth control in Saccharomyces cerevisiae mutants lacking PMC1, a homolog of plasma membrane Ca2+ ATPases. 1994 J. Cell Biol. pmid:7507493
Wang T et al. Specific interaction of type I receptors of the TGF-beta family with the immunophilin FKBP-12. 1994 Science pmid:7518616
Fealy MJ et al. Efficacy of rapamycin and FK 506 in prolonging rat hind limb allograft survival. 1994 Ann. Surg. pmid:7507657
Tanabe M et al. Combined immunosuppressive therapy with low dose FK506 and antimetabolites in rat allogeneic heart transplantation. 1994 Transplantation pmid:7518619
Bossard MJ et al. Catalytic and ligand binding properties of the FK506 binding protein FKBP12: effects of the single amino acid substitution of Tyr82 to Leu. 1994 Biochem. J. pmid:7507662
Tamura K et al. Interaction of tacrolimus(FK506) and its metabolites with FKBP and calcineurin. 1994 Biochem. Biophys. Res. Commun. pmid:7518678
Hooks MA Tacrolimus, a new immunosuppressant--a review of the literature. 1994 Ann Pharmacother pmid:7518710
Frizell E et al. FK506 enhances fibrogenesis in in vitro and in vivo models of liver fibrosis in rats. 1994 Gastroenterology pmid:7518783
Fujimura A and Ebihara A Administration time-dependent toxicity of a new immunosuppressive agent, tacrolimus (FK 506). 1994 Life Sci. pmid:7518886
Gottschalk AR et al. Identification of immunosuppressant-induced apoptosis in a murine B-cell line and its prevention by bcl-x but not bcl-2. 1994 Proc. Natl. Acad. Sci. U.S.A. pmid:7518929
Chen CL et al. FK 506 used as rescue therapy for refractory liver allograft rejection. 1994 Transplant. Proc. pmid:7520612
Nakata S et al. Immunosuppressive mechanisms of deoxymethylspergualin and FK 506 on in vitro cytotoxic T lymphocytes. 1994 Transplant. Proc. pmid:7520613
Morphopathological findings of renal allografts under FK 506 therapy. Japanese FK 506 Study Group. 1994 Transplant. Proc. pmid:7520614
Imanishi M et al. Induction of tolerance by intrathymic injection of donor bone marrow cells in the rat: simultaneous heart and skin allograft model. 1994 Transplant. Proc. pmid:7520615
Charters AR et al. Immunochemical analysis of FK506 binding proteins in neuronal cell lines and rat brain. 1994 Biochem. Soc. Trans. pmid:7535258
Matsuura T et al. Organ-specific tolerance induced by intrathymic injection of donor bone marrow cells and FK 506 or antilymphocyte serum in rat heart transplantation. 1994 Transplant. Proc. pmid:7520616
Andoh TF et al. Enhancement of FK506 nephrotoxicity by sodium depletion in an experimental rat model. 1994 Transplantation pmid:7509514
Charters AR et al. The subcellular distribution of FK506 binding proteins in rat brain. 1994 Biochem. Soc. Trans. pmid:7535259
Ota K Living donor kidney transplantation in Japan. 1994 Transplant. Proc. pmid:7520622
Hirose M and Kuroda Y Reinforcement of cyclosporin A-induced red cell destruction by superoxide. 1994 Tokushima J. Exp. Med. pmid:7535479
Takahara S et al. Monitoring of FK 506 blood levels in kidney transplant recipients. 1994 Transplant. Proc. pmid:7520623
Sun CK et al. Intensive care after orthotopic liver transplantation. 1994 Transplant. Proc. pmid:7520627
Surdacka E et al. [New immunosuppressive drugs in transplantation]. 1994 Prz. Lek. pmid:7532870
Tai PK et al. Potentiation of progesterone receptor-mediated transcription by the immunosuppressant FK506. 1994 Biochemistry pmid:7521210
Akita K et al. Suppression of nitric oxide production by cyclosporin A and FK506A in rat vascular smooth muscle cells. 1994 Clin. Exp. Pharmacol. Physiol. pmid:7521274
Weaver JL et al. The interaction of immunosuppressive compounds in tandem stimulated peripheral human lymphocytes. 1994 Immunopharmacol Immunotoxicol pmid:7521360
Woo J et al. FK506 inhibits the differentiation of developing thymocytes but not negative selection of T cell receptor V beta 5+ and V beta 11+ T lymphocytes in vivo. 1994 Transpl. Immunol. pmid:7521743
Kasiske BL The effects of immunosuppressive agents on plasma lipoproteins after organ transplantation. 1994 J. Lab. Clin. Med. pmid:7521894
Krentz AJ et al. Serum lipids and apolipoproteins in liver transplant recipients: a comparative study of cyclosporin A and FK 506. 1994 J. Lab. Clin. Med. pmid:7521895
Jensen C et al. Interaction between tacrolimus and erythromycin. 1994 Lancet pmid:7521928
Clipstone NA et al. Molecular analysis of the interaction of calcineurin with drug-immunophilin complexes. 1994 J. Biol. Chem. pmid:7523407
Karmann K et al. Endothelial cell-induced resistance to cyclosporin A in human peripheral blood T cells requires contact-dependent interactions involving CD2 but not CD28. 1994 J. Immunol. pmid:7523510
Wakabayashi H et al. The effect of FK506 on warm ischemia and reperfusion injury in the rat liver. 1994 Surg. Today pmid:7539646
Hiromura K et al. FK506 inhibits renal glomerular thrombosis induced in rats by nephrotoxic serum and lipopolysaccharide. 1994 Kidney Int. pmid:7523750
Ohtomo Y et al. Coexisting NPY and NE synergistically regulate renal tubular Na+, K(+)-ATPase activity. 1994 Kidney Int. pmid:7523751
Siekierka JJ Probing T-cell signal transduction pathways with the immunosuppressive drugs, FK-506 and rapamycin. 1994 Immunol. Res. pmid:7539823
Moore R and Lord R Tacrolimus (FK506) versus cyclosporin in prevention of liver allograft rejection. 1994 Lancet pmid:7523805
Krentz AJ et al. Tacrolimus (FK506) versus cyclosporin in prevention of liver allograft rejection. 1994 Lancet pmid:7523806
Collins RH Tacrolimus (FK506) versus cyclosporin in prevention of liver allograft rejection. 1994 Lancet pmid:7523807
Schmidt A et al. Two FK506 resistance-conferring genes in Saccharomyces cerevisiae, TAT1 and TAT2, encode amino acid permeases mediating tyrosine and tryptophan uptake. 1994 Mol. Cell. Biol. pmid:7523855
Milan D et al. The latch region of calcineurin B is involved in both immunosuppressant-immunophilin complex docking and phosphatase activation. 1994 Cell pmid:7525078
Tamir H et al. Secretogogue-induced gating of chloride channels in the secretory vesicles of parafollicular cells. 1994 Endocrinology pmid:7525261
Shafiee A et al. Enzymology of FK-506 biosynthesis. Purification and characterization of 31-O-desmethylFK-506 O:methyltransferase from Streptomyces sp. MA6858. 1994 Eur. J. Biochem. pmid:7525282
Benton BM et al. A novel FK506- and rapamycin-binding protein (FPR3 gene product) in the yeast Saccharomyces cerevisiae is a proline rotamase localized to the nucleolus. 1994 J. Cell Biol. pmid:7525596
Gruber SA et al. Pharmacokinetics of FK506 after intravenous and oral administration in patients awaiting renal transplantation. 1994 J Clin Pharmacol pmid:7525661
Funk JO and Maibach HI Horizons in pharmacologic intervention in allergic contact dermatitis. 1994 J. Am. Acad. Dermatol. pmid:7525668
Mukaida N et al. Molecular mechanism of interleukin-8 gene expression. 1994 J. Leukoc. Biol. pmid:7525815
Hiromatsu Y et al. Inhibitory effect of FK506 on intercellular adhesion molecule-1 (ICAM-1) expression on cultured thyroid cells. 1994 Kurume Med J pmid:7526029
Matsunami H et al. New technique for measuring tacrolimus concentrations in blood. 1994 Am J Hosp Pharm pmid:7510929
Renoir JM et al. Effects of immunosuppressants FK506 and rapamycin on the heterooligomeric form of the progesterone receptor. 1994 J. Steroid Biochem. Mol. Biol. pmid:7510997
Devlin J et al. Renal complications and development of hypertension in the European study of FK 506 and cyclosporin in primary liver transplant recipients. 1994 Transpl. Int. pmid:11271207
Two-year follow-up study of the efficacy and safety of FK 506 in kidney transplant patients. Japanese FK 506 Study Group. 1994 Transpl. Int. pmid:11271216
Neuhaus P et al. Neurological complications in the European multicentre study of FK 506 and cyclosporin in primary liver transplantation. 1994 Transpl. Int. pmid:11271222
Bismuth H et al. Focus on intractable rejection: 6-month results of the European multicentre liver study of FK 506 and cyclosporin A. 1994 Transpl. Int. pmid:11271231
McMaster P Patient and graft survival in the European Multicentre Liver Study--FK 506 vs cyclosporin A. 1994 Transpl. Int. pmid:11271239
Mueller AR et al. Neurotoxicity after orthotopic liver transplantation in cyclosporin A- and FK 506-treated patients. 1994 Transpl. Int. pmid:11271254
D'Silva M et al. The immunomodulatory effects of a novel agent, leflunomide, in rat cardiac allotransplantation. 1994 Transpl. Int. pmid:11271257
Trocha K et al. Neurological examinations after liver transplantation concerning patients under corticosteroid immunosuppression and either FK 506 or cyclosporin. 1994 Transpl. Int. pmid:11271273
Lea JP et al. Evidence that the inhibition of Na+/K(+)-ATPase activity by FK506 involves calcineurin. 1994 Kidney Int. pmid:7527873
Nielsen FT et al. Nephrotoxity of FK 506: a preliminary study on comparative aspects of FK 506 and cyclosporine nephrotoxicity. 1994 Transplant. Proc. pmid:7527946
Fisher A et al. Gastrointestinal toxicity associated with FK 506 in liver transplant recipients. 1994 Transplant. Proc. pmid:7527947